medigraphic.com
ISSN 0016-3813 (Print)

2017, Number 2

<< Back Next >>

Gac Med Mex 2017; 153 (2)

Seroprevalence of Trypanosoma cruzi (TC) and risk factors in Colima, Mexico

Newton-Sánchez OA, Espinoza-Gómez F, Melnikov V, Delgado-Enciso I, Rojas-Larios F, Dumonteil E, Trujillo-Hernández B, de la Cruz-Ruiz M

Language: English
References: 28
Page: 179-184
PDF size: 97.16 Kb.


ABSTRACT

Introduction: The present study was conducted to estimate the incidence of seropositivity to anti-Trypanosoma cruzi antibodies and analyze potential risk factors in Colima, on the western coast of Mexico. Methodology: Longitudinal studies of 209 subjects with negative serology in 1999 for anti-Trypanosoma cruzi antibodies by hemagglutination inhibition test were tested again in 2005. At the same time, 716 children under six years of age were surveyed serologically (total n = 925); the history of Trypanosoma cruzi infection was determined by the same hemagglutination inhibition test. The variables analyzed were age, sex, living in triatomine-infested places, type of community, quality of housing, presence of pets, and number of inhabitants per house. Results: Trypanosoma cruzi seropositivity in the period of six years was 22/925 cases, with a point prevalence of 2.73% and an adjusted rate of 7.3/1,000 person-years. The variable living in triatomine-infested areas showed association with seropositivity anti-Trypanosoma cruzi antibodies (RR: 5.5; 95% CI: 1.28-23.5). The remaining variables showed no significant association. Conclusions: This study confirms the active transmission of Chagas disease in Mexico´s western- central region, which merits greater epidemiological surveillance and vector control, particularly in localities infested with triatomines.


REFERENCES

  1. Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz. 2009;104:17-30.

  2. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:1388-402.

  3. Sarkar S, Strutz SE, Frank DM, Rivaldi CL, Sissel B, Sánchez-Cordero V. Chagas disease risk in Texas. PLoS Negl Trop Dis. 2010;4:e836.

  4. Dias JCP, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz. 2002;97:603-12

  5. Cruz-Reyes A, Pickering-López JM. Chagas disease in Mexico: an analysis of geographical distribution during the past 76 years - A review. Mem Inst Oswaldo Cruz. 2006;101:345-54.

  6. Bottazzi ME, Dumonteil E, Valenzuela JG, Betancourt-Cravioto M, Tapia-Conyer R, Hotez PJ. Bridging the innovation gap for neglected tropical diseases in Mexico: capacity building for the development of a new generation of antipoverty vaccines. Bol Med Hosp Infant Mex. 2010;68:138-46.

  7. Wendel S. Transfusion transmitted Chagas disease: is it really under control? Acta Trop. 2010;115:28-34.

  8. Belaunzarán ML. Chagas disease: Globalization and new hope for its cure. Rev Argent Microbiol. 2015;47: 85-7.

  9. Oliveira I, Torrico F, Muñoz J, Gascon J. Congenital transmission of Chagas disease: a clinical approach. Expert Rev Anti Infect Ther. 2010; 8:945-56.

  10. Buekens P, Almendares O, Carlier Y, et al. Mother-to-child transmission of Chagas’ disease in North America: Why don’t we do more? Matern Child Health J. 2008;12:283-6.

  11. Medina-Torres I, Vázquez-Chagoyán JC, Rodríguez-Vivas RI, de Oca- Jiménez RM. Risk factors associated with triatomines and its infection with Trypanosoma cruzi in rural communities from the southern region of the State of Mexico, Mexico. Am J Trop Med Hyg. 2010;82:49-54.

  12. Espinoza-Gómez F, Maldonado-Rodríguez A, Coll-Cárdenas R, Hernández- Suárez CM, Fernández-Salas I. Presence of triatominae (Hemiptera, Reduviidae) and risk of transmission of Chagas disease in Colima, México. Mem Inst Oswaldo Cruz. 2002;97:25-30.

  13. Coll-Cárdenas R, Espinoza-Gómez F, Maldonado-Rodríguez A, Reyes- López PA, Huerta-Viera M, Rojas-Larios F. Active transmission of human Chagas disease in Colima Mexico. Mem Inst Oswaldo Cruz. 2004;99:363-8.

  14. Instituto Nacional de Estadística Geografía e Informática (INEGI). (2010). Censo Nacional de población 2010. INEGI, México, 2010. http://www3. inegi.org.mx/sistemas/sisept/Default.aspx?t=mdemo148&s=est&c=29192.

  15. De Andrade AL, Zicker F, De Oliveira RM, et al. Evaluation of risk factors for house infestation by Triatoma infestans in Brazil. Am J Trop Med Hyg. 1995;53:443-7.

  16. Schofield CJ. A comparison of sampling techniques for domestic populations of Triatominae. Trans R Soc Trop Med Hyg. 1978;72:449-55.

  17. Wiener labs. Chagatest, HAI. Prueba de hemaglutinación indirecta para la detección de anticuerpos contra el Trypanosoma cruzi. Rosario, Argentina. 2000. Available at: http://www.wiener-lab.com.ar

  18. Abramson JH, Gahlinger PM: Computer Programs for Epidemiologists: PEPI Version 3.00. Llanidloes, Wales: Brixton Books; 1999.

  19. Blejer JL, Saguier MC, Dinapoli RA, Salamone HJ. [Prevalence of Trypanosoma cruzi antibodies in blood donors]. Medicina (B Aires). 1999;59:129-32.

  20. Bergmann-Araújo A, Aires-Berne MA. Conventional serological performance in diagnosis of Chagas’ disease in southern Brazil. Braz J Infect Dis. 2013;17:174-8.

  21. Duarte LF, Flores O, Rincón G, González CI. Comparison of seven diagnosis tests to detect Trypanosoma cruzi infection in patients in chronic phase of Chagas disease. Colombia Medica. 2014;45:61-6.

  22. Sosa-Jurado F, Zumaquero-Ríos JL, Reyes PA, Cruz-García A, Guzmán- Bracho C, Monteón VM. Factores bióticos y abióticos que determinan la seroprevalencia de anticuerpos contra Trypanosoma cruzi en el municipio de Palmar de Bravo, Puebla, México. Salud Publica Mex. 2004;46:39-48

  23. Salazar PM, Rojas G, Bucio M, et al. [Seroprevalence of Trypanosoma cruzi antibodies and associated risk factors among the population under 18 years of age in Veracruz, Mexico]. Rev Panam Salud Publica. 2007;22:75-82.

  24. Organización Mundial de la Salud. Control de la Enfermedad de Chagas. Segundo Informe del Comité de Expertos de la OMS. Ginebra 2002:26-31.

  25. Ramsey JM, Alvear AL, Ordoñez R, et al. Risk factors associated with house infestation by the Chagas disease vector Triatoma pallidipennis in Cuernavaca metropolitan area, Mexico. Med Vet Entomol. 2005:19:219- 28.

  26. Mougabure-Cueto G, Picollo MA. Insecticide resistance in vector Chagas disease: evolution, mechanisms and management. Acta Tropica. 2015;149:70-85.

  27. Comité Consultivo Nacional de Normalización de Prevención y Control de Enfermedades. Norma Oficial Mexicana NOM-032-SSA2-2010, Para la vigilancia epidemiológica, prevención y control de las enfermedades transmitidas por vector. Diario Oficial de la Federación, México, 01 junio 2011:22-24.

  28. Salazar-Schetinno PM, Cravioto A, Tapia-Conver R. Iniciativa México: propuesta para el control y vigilancia epidemiológica de la enfermedad de Chagas en México. Bol Chil Parasitol. 2011;56:76-9.




2020     |     www.medigraphic.com